In the press

David Batchelor comments on SMT’s update in Investment Week

Biotech trusts top performance charts in February

David Batchelor comments on SMT’s technology exposure in Michael Nelson’s article:

“The recent market nervousness over the scale and prospective returns from that spending will provide a fresh test of those positions, particularly with SMT’s five-year NAV return still well behind its benchmark.”

Read more here